These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

687 related articles for article (PubMed ID: 30345399)

  • 1. CRISPR-Cas9/Cas12a biotechnology and application in bacteria.
    Yao R; Liu D; Jia X; Zheng Y; Liu W; Xiao Y
    Synth Syst Biotechnol; 2018 Sep; 3(3):135-149. PubMed ID: 30345399
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Class 2 CRISPR/Cas: an expanding biotechnology toolbox for and beyond genome editing.
    Tang Y; Fu Y
    Cell Biosci; 2018; 8():59. PubMed ID: 30459943
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Recent advances of Cas12a applications in bacteria.
    Meliawati M; Schilling C; Schmid J
    Appl Microbiol Biotechnol; 2021 Apr; 105(8):2981-2990. PubMed ID: 33754170
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Cas9 versus Cas12a/Cpf1: Structure-function comparisons and implications for genome editing.
    Swarts DC; Jinek M
    Wiley Interdiscip Rev RNA; 2018 Sep; 9(5):e1481. PubMed ID: 29790280
    [TBL] [Abstract][Full Text] [Related]  

  • 5. CRISPR/Cas System: Recent Advances and Future Prospects for Genome Editing.
    Manghwar H; Lindsey K; Zhang X; Jin S
    Trends Plant Sci; 2019 Dec; 24(12):1102-1125. PubMed ID: 31727474
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Application of different types of CRISPR/Cas-based systems in bacteria.
    Liu Z; Dong H; Cui Y; Cong L; Zhang D
    Microb Cell Fact; 2020 Sep; 19(1):172. PubMed ID: 32883277
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Advances in CRISPR-Cas systems for RNA targeting, tracking and editing.
    Wang F; Wang L; Zou X; Duan S; Li Z; Deng Z; Luo J; Lee SY; Chen S
    Biotechnol Adv; 2019; 37(5):708-729. PubMed ID: 30926472
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Discovery of Diverse CRISPR-Cas Systems and Expansion of the Genome Engineering Toolbox.
    Koonin EV; Gootenberg JS; Abudayyeh OO
    Biochemistry; 2023 Dec; 62(24):3465-3487. PubMed ID: 37192099
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Functional Features and Current Applications of the RNA-Targeting Type VI CRISPR-Cas Systems.
    Perčulija V; Lin J; Zhang B; Ouyang S
    Adv Sci (Weinh); 2021 Jul; 8(13):2004685. PubMed ID: 34254038
    [TBL] [Abstract][Full Text] [Related]  

  • 10. [The new generation tool for CRISPR genome editing: CRISPR/Cpf1].
    Yang F; Li Y
    Sheng Wu Gong Cheng Xue Bao; 2017 Mar; 33(3):361-371. PubMed ID: 28941336
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Harnessing CRISPR/Cas systems for programmable transcriptional and post-transcriptional regulation.
    Mahas A; Neal Stewart C; Mahfouz MM
    Biotechnol Adv; 2018; 36(1):295-310. PubMed ID: 29197619
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Harnessing the type I CRISPR-Cas systems for genome editing in prokaryotes.
    Xu Z; Li Y; Li M; Xiang H; Yan A
    Environ Microbiol; 2021 Feb; 23(2):542-558. PubMed ID: 32510745
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Applications of CRISPR-Cas in agriculture and plant biotechnology.
    Zhu H; Li C; Gao C
    Nat Rev Mol Cell Biol; 2020 Nov; 21(11):661-677. PubMed ID: 32973356
    [TBL] [Abstract][Full Text] [Related]  

  • 14. RNA-Independent DNA Cleavage Activities of Cas9 and Cas12a.
    Sundaresan R; Parameshwaran HP; Yogesha SD; Keilbarth MW; Rajan R
    Cell Rep; 2017 Dec; 21(13):3728-3739. PubMed ID: 29281823
    [TBL] [Abstract][Full Text] [Related]  

  • 15. CRISPR/Cas-Based Modifications for Therapeutic Applications: A Review.
    Bharathkumar N; Sunil A; Meera P; Aksah S; Kannan M; Saravanan KM; Anand T
    Mol Biotechnol; 2022 Apr; 64(4):355-372. PubMed ID: 34741732
    [TBL] [Abstract][Full Text] [Related]  

  • 16. CRISPR-Cas13 technology portfolio and alliance with other genetic tools.
    Wu S; Tian P; Tan T
    Biotechnol Adv; 2022 Dec; 61():108047. PubMed ID: 36208845
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Genome editing by natural and engineered CRISPR-associated nucleases.
    Wu WY; Lebbink JHG; Kanaar R; Geijsen N; van der Oost J
    Nat Chem Biol; 2018 Jul; 14(7):642-651. PubMed ID: 29915237
    [TBL] [Abstract][Full Text] [Related]  

  • 18. The Conspicuity of CRISPR-Cpf1 System as a Significant Breakthrough in Genome Editing.
    Bayat H; Modarressi MH; Rahimpour A
    Curr Microbiol; 2018 Jan; 75(1):107-115. PubMed ID: 29189942
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Directed Evolution of CRISPR/Cas Systems for Precise Gene Editing.
    Liu R; Liang L; Freed EF; Gill RT
    Trends Biotechnol; 2021 Mar; 39(3):262-273. PubMed ID: 32828556
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Systematic discovery of natural CRISPR-Cas12a inhibitors.
    Watters KE; Fellmann C; Bai HB; Ren SM; Doudna JA
    Science; 2018 Oct; 362(6411):236-239. PubMed ID: 30190307
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 35.